[EN] COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS UTILISABLES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
申请人:SCHERING CORP
公开号:WO2010054279A1
公开(公告)日:2010-05-14
This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases
作者:Vinay M. Girijavallabhan、Lei Chen、Chaoyang Dai、Robert J. Feltz、Luke Firmansjah、Dansu Li、Seong Heon Kim、Joseph A. Kozlowski、Brian J. Lavey、Aneta Kosinski、John J. Piwinski、Janeta Popovici-Muller、Razia Rizvi、Kristin E. Rosner、Banderpalle B. Shankar、Neng-Yang Shih、M. Arshad Siddiqui、Ling Tong、Michael K.C. Wong、De-yi Yang、Liping Yang、Wensheng Yu、Guowei Zhou、Zhuyan Guo、Peter Orth、Vincent Madison、Hong Bian、Daniel Lundell、Xiaoda Niu、Himanshu Shah、Jing Sun、Shelby Umland
DOI:10.1016/j.bmcl.2010.10.081
日期:2010.12
Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors has led to an acetylene containing series that demonstrates sub-nanomolar potency (Ki) as well as excellent activity in human whole blood. These studies led to the discovery of highly potent TACE inhibitors with good DMPK profiles.
COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
申请人:Merck Sharp & Dohme Corp.
公开号:EP2346857B1
公开(公告)日:2019-11-27
.alpha.-Ethynyl and .alpha.-vinyl analogs of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase
作者:Charles Danzin、Patrick Casara、Nicole Claverie、Brian W. Metcalf
DOI:10.1021/jm00133a005
日期:1981.1
alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 10 and 810 microM, and the times of half-inactivation at infinite concentration of inhibitor (t1/2) are 8.5 and 27 min, respectively, for alpha-ethynyl- and alpha-vinylornithine. In rats, alpha-ethynylornithine causes a rapid dose-dependent decrease of ornithine decarboxylase activity in prostate and, to a lesser extent, in thymus and testis.